1. Convalescent Plasma to Treat COVID-19
2. Food and Drug Administration (FDA).Recommendations for Investigational COVID‐19 Convalescent Plasma.https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasmaAccessed August 10 2020.
3. Adverse reactions in whole blood donors: an Indian scenario;Pathak C;Blood Transfus,2011
4. International society of blood transfusion working party on haemovigilance in collaboration with the international haemovigilance network and the AABB donor haemovigilance working group. Standard for Surveillance of Complications Related to Blood Donation.http://aabb.org/research/hemovigilance/Documents/Donor-Standard-Definitions.pdfAccessed June 26 2020.
5. Advancing transfusion and cellular therapies worldwide.AABB Donor hemovigilance report 2012‐2014.http://www.aabb.org/research/hemovigilance/Documents/2012-2014-AABB-Donor-Hemovigilance-Report.pdfAccessed August 10 2020.